rheumatology
Medicines

Appeal over $6 million penalty for Nurofen rejected

A failed high court appeal means the company that manufactures Nurofen must pay a $6 million penalty it was handed for misleading consumers with its pain relief range. The penalty, revised up from an initial $1.7 million, is the highest ever issued for misleading conduct under Australian Consumer Law. The ACCC accused manufacturer Reckitt Benckiser ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic